Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-Analysis.

NeurologySep 16, 2026 (epub)
Clinical ResearchNeurologyCardiology

Aristeidis H Katsanos, Ashkan Shoamanesh, Lina Palaiodimou et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of Factor XIa inhibitors in patients with noncardioembolic ischemic stroke or transient ischemic attack (TIA). Analyzing data from three randomized-controlled trials involving 14,239 participants, the study found that FXIa inhibitors significantly reduced the risk of any stroke (RR = 0.75; 95% CI 0.66-0.84) compared to placebo, without increasing major bleeding risk.

Key findings

  • FXIa inhibitors reduced the risk of any stroke (RR = 0.75; 95% CI 0.66-0.84) compared to placebo.
  • Ischemic stroke risk was reduced (RR = 0.74; 95% CI 0.66-0.84) with FXIa inhibitors.
  • Composite cardiovascular events were lower with FXIa inhibitors (RR = 0.83; 95% CI 0.75-0.92).
  • No increase in major bleeding risk was observed (RR = 1.12; 95% CI 0.87-1.44).

Why it matters

The findings suggest that incorporating FXIa inhibitors into treatment regimens for patients with noncardioembolic ischemic stroke or TIA may enhance secondary prevention strategies, potentially reducing recurrent stroke risk without compromising safety.

Source

PubMed · PMID 42748394

Published in Neurology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.